To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2

Inclusion Criteria: 1. Voluntary consent to participate in the study and signed the informed consent form. 2. Male or female, age 18-75 years (including both). 3. Histologic confirmed non-muscle invasive bladder urothelial carcinoma (NMIBC), and the risk group met the high-risk (including very high-risk) group. Note: High-risk NMIBC is a high-grade / G3 tumor meeting any of the following: a.Carcinoma in situ (CIS) b. T1 stage c. diameter\>3cm d.Multiple tumors, or recurrent tumors. 4. Absence of resectable disease（Ta and/or T1 disease） after transurethral resection (TURBT) procedures (residual CIS acceptable; 5. The urologist assessed that radical surgery for bladder cancer was not suitable or the subject refused radical surgery for bladder cancer. 6. Tumor tissue samples were detected by immunohistochemistry (IHC) to satisfy HER2 expression of 1+, 2+ or 3+. 7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 8. Adequate heart, bone marrow, liver, kidney and coagulation function Exclusion Criteria: * 1\. Invasive bladder cancer (T2 and above) and / or with regional lymph node and distant metastasis. 2\. Combined urothelial carcinoma outside the bladder (i. e., urethra, ureter or renal pelvis). 3\. Any other antitumor therapy received within 4 weeks before study administration, . 4 Subjects plan to undergo major surgery during the study or within 4 weeks before the first dose. 5, Known allergic to DV and its components or to any excipients.